Key Financial Figures for the Nine-Month Period 2025
Posted at h
in Announcements
Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared to €9.42 million in the corresponding period of the previous year. Adjusted EBITDA from continuing operations amounted to €9.52 million versus €9.28 million in the same period last year, marking a 2.7% increase